Biotech | April 13, 2022
Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The total investment is in the region of Rs 200 crore
Both companies have been selected for stand-by production by German government
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
The hospital is committed to adding to specialised practices in the healthcare space with its pioneering effort to promote oral health awareness and tobacco addiction prevention
About 96% of all 15+ population in the country have received at least one Covid-19 vaccine dose while about 83% of 15+ population has received both the doses
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Subscribe To Our Newsletter & Stay Updated
